Are Allergy Shots Safe? What 54 Million Injection Visits Tell Us

Serious systemic reactions occur in approximately 0.1-0.2% of allergy shot injection visits, according to the AAAAI/ACAAI National Surveillance Study covering over 54 million injection visits (Epstein 2019). The majority of these reactions — about 74% — are mild Grade 1 reactions involving a single organ system like skin or upper airway. Severe Grade 3 reactions occur in roughly 1 per 300,000 visits, and Grade 4 anaphylaxis in approximately 1 per 160,000 visits. Fatal reactions are now exceedingly rare at roughly 1 per 9 million injection visits, far lower than the 1 per 2.5 million rate observed in the 1990s before modern safety protocols were universally adopted. The 30-minute observation period catches approximately 85% of all systemic reactions.

Allergy shot safety has improved approximately 3.75-fold since the 1990-2001 era, driven by three key practice changes identified through AAAAI/ACAAI fatality surveillance. First, mandatory asthma screening before each injection — since uncontrolled asthma was present in 88% of fatal reactions (Bernstein 2004), deferring injections on days when a patient's asthma is poorly controlled removes the dominant risk factor. Second, peak-season dose reduction protocols — studies show that practices consistently reducing doses during patients' primary pollen season had significantly fewer Grade 2-3 systemic reactions (44% vs. 65%, Epstein 2013). Third, strict adherence to Practice Parameter protocols including 50% dose reduction at new vial transitions and immediate availability of epinephrine at every injection visit. These evidence-based safeguards collectively account for the dramatically improved modern safety record.

Several patient groups face elevated risk and require additional precautions or shared decision-making before starting allergy shots. Patients with uncontrolled asthma are the highest-risk group — injections should be deferred on any day when lung function falls below 70% of predicted FEV1. Patients taking beta-blocker medications face impaired epinephrine response if anaphylaxis occurs, making rescue treatment less effective; this requires an informed discussion with your allergist. Those with a prior systemic reaction to allergy shots have a four-fold higher recurrence rate (Roy 2007). Patients with mastocytosis or elevated baseline tryptase tend to experience more severe anaphylaxis during immunotherapy. Elderly patients with cardiovascular comorbidities and women in early pregnancy (where initiation is not recommended, though continuation is generally safe) also warrant individualized risk assessment.

Yes, the 30-minute observation period is a medically established standard of care with a strong evidence basis. Approximately 85% of all systemic reactions occur within 30 minutes of injection, which is why the rule exists (Epstein 2011, 2019). Most fatal reactions in historical surveillance also began within the first 20-25 minutes. However, 15% of systemic reactions do occur after 30 minutes, so patients should remain alert for new symptoms — particularly hives, throat tightness, wheezing, or dizziness — in the hours following each injection. The risk of a delayed reaction is higher during build-up, after new vial transitions, and during peak pollen season. Patients with a history of systemic reactions may benefit from an extended observation period of 45-60 minutes per EAACI recommendations.

The long-term safety data for allergy shots is reassuring. A large Danish nationwide registry study (Linneberg 2012, JACI) found that patients who received SCIT had lower rates of autoimmune disease, lower acute myocardial infarction risk, and lower all-cause mortality compared with patients using conventional pharmacotherapy. No increased cancer risk has been documented in over a century of clinical use. The PAT study's 10-year follow-up (Jacobsen 2007) found no new long-term safety signals in children who completed three years of SCIT. Aluminum-adsorbed depot extracts used more commonly in Europe have been associated with rare subcutaneous nodules at injection sites, but this is uncommon with the aqueous and glycerinated extracts typically used in U.S. practice. No chronic immunosuppression, increased infection risk, or organ toxicity has emerged in long-term cohort studies.

Allergy shots can be continued safely during pregnancy but should not be initiated during pregnancy. The 2011 AAAAI/ACAAI Practice Parameter is explicit on this distinction: continuation at the current maintenance dose is appropriate, but dose escalation should not occur during pregnancy because a systemic reaction could cause fetal hypoxia or uterine contractions. Several studies support the safety of continuation. A Swedish nationwide registry of 924,790 pregnancies including 743 with allergy immunotherapy exposure (Larsson 2022) found no association with congenital malformations, preterm birth, stillbirth, or cesarean delivery. If pregnancy begins during the build-up phase at sub-therapeutic doses, discontinuation should be considered. Venom immunotherapy for life-threatening sting allergy is an exception where benefit-risk may favor continuation even during initiation.

Allergy shots produce beneficial, lasting changes to immune function — this is precisely what makes them disease-modifying rather than just symptom-suppressing. SCIT induces regulatory T cells that secrete IL-10 and TGF-beta, shifts the immune response from allergic Th2 dominance toward tolerance, and generates allergen-specific IgG4 blocking antibodies that compete with IgE for allergen binding. These changes reduce both the early- and late-phase allergic response. Long-term, the PAT study found that children who completed SCIT were significantly less likely to develop asthma — 25% vs. 45% in controls at 10-year follow-up (Jacobsen 2007, Allergy). SCIT also reduces the likelihood of developing new allergen sensitivities in pediatric patients. No harmful long-term immune effects — chronic immunosuppression, increased infection susceptibility, or immune dysregulation — have been documented in long-term cohorts.